Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) ROCE % : 0.00% (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cotinga Pharmaceuticals's annualized ROCE % for the quarter that ended in Jan. 2020 was 0.00%.

Cotinga Pharmaceuticals ROCE % Historical Data

The historical data trend for Cotinga Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals ROCE % Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

ROCE %

Get a 7-Day Free Trial

-233.05

-178.73

-252.38

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Cotinga Pharmaceuticals ROCE % Calculation

Cotinga Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Apr. 2019 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2019 )		(A: Apr. 2018 )		(A: Apr. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2019 )		(A: Apr. 2018 )		(A: Apr. 2019 )
	=	-2.055	/	( ( (1.203 - 2.445)	+	(0.933 - 2.727) )	/ 2 )
	=	-2.055	/	( (-1.242	+	-1.794)	/ 2 )
	=	-2.055	/	-1.518
	=	135.38 %

Cotinga Pharmaceuticals's ROCE % of for the quarter that ended in Jan. 2020 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2020 )		(Q: Oct. 2019 )		(Q: Jan. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2020 )		(Q: Oct. 2019 )		(Q: Jan. 2020 )
	=	-1.44	/	( ( (0.715 - 3.269)	+	(0.695 - 3.677) )	/ 2 )
	=	-1.44	/	( ( -2.554	+	-2.982 )	/ 2 )
	=	-1.44	/	-2.768
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2020) EBIT data.

Cotinga Pharmaceuticals (OTCPK:COTQF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cotinga Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018